‘Ground-breaking’ diabetes insulin drug trialled in Cardiff

‘Ground-breaking’ diabetes insulin drug trialled in Cardiff

  • September 11, 2018
Table of Contents

‘Ground-breaking’ diabetes insulin drug trialled in Cardiff

A ‘ground-breaking’ drug that helps people with diabetes re-grow insulin-making cells has been developed. About 19,000 people live with Type 1 of the condition in Wales and 90% have less than 5% of these cells left. This means they have to inject insulin

but it is hoped the new drug will mean patients may not have to in the future. The trials are being conducted by researchers at Cardiff and Vale University Health Board and two people have already been given the drug. The new drug could mean they are no longer dependent on injecting it and this will potentially reduce many of the problems associated with the chronic disease.

While the majority of diabetics (about 170,000) have Type 2, diabetes costs the NHS in Wales approximately £500m a year, 10% of its annual budget. The first two patients in the world have been dosed with the investigational drug, which helps re-grow insulin-making beta cells of the pancreas, lost in patients living with the disease. They were closely monitored over 72 hours and so far, neither has had any major side effects.

The research team is now looking to recruit eight people who have had diabetes for more than two years to take part in wider-ranging trials. The Welsh Government’s Health and Care Research Wales team helps collaborations and the organisation’s Carys Thomas said the work could prove ‘ground-breaking’.

Source: bbc.com

Share :
comments powered by Disqus

Related Posts

Cancer cells engineered with CRISPR slay their own kin

Cancer cells engineered with CRISPR slay their own kin

Using gene editing, scientists have hoodwinked tumor cells into turning against their own kind. Cancer cells circulating in the bloodstream have something of a homing instinct, able to find and return to the tumor where they originated. To capitalize on that ability, researchers engineered these roving tumor cells to secrete a protein that triggers a death switch in resident tumor cells they encounter.

Read More
AI System Approved For Diabetic Retinopathy Diagnosis

AI System Approved For Diabetic Retinopathy Diagnosis

A system designed by a University of Iowa ophthalmologist that uses artificial intelligence (AI) to detect diabetic retinopathy without a person interpreting the results earned Food and Drug Administration (FDA) authorization in April, following a clinical trial in primary care offices. Results of that study were published Aug. 28 online in Nature Digital Medicine, offering the first look at data that led to FDA clearance for IDx-DR, the first medical device that uses AI for the autonomous detection of diabetic retinopathy. The clinical trial, which also was the first study to prospectively assess the safety of an autonomous AI system in patient care, compared the performance of IDx-DR to the gold standard diagnostic for diabetic retinopathy, which is the leading cause of vision loss in adults and one of the most severe complications for the 30.3 million Americans living with diabetes.

Read More
New anti-cancer drugs put cancers to sleep—permanently

New anti-cancer drugs put cancers to sleep—permanently

In a world first, Melbourne scientists have discovered a new type of anti-cancer drug that can put cancer cells into a permanent sleep, without the harmful side-effects caused by conventional cancer therapies. Published today in the journal Nature, the research reveals the first class of anti-cancer drugs that work by putting the cancer cell to sleep – arresting tumour growth and spread without damaging the cells’ DNA. The new class of drugs could provide an exciting alternative for people with cancer, and has already shown great promise in halting cancer progression in models of blood and liver cancers, as well as in delaying cancer relapse.

Read More